Rolvedon

eflapegrastim

Approval

ApplicationBLA 761148
Approval dateSep 9, 2022
Approval year2022
SponsorSpectrum Pharms

FDA-approved use

To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Rolvedon: